晚期非小细胞肺癌患者的生存率改善
Keishi Yoshida1, Kaoru Watanabe2, Taku Nishimura1
1Department of Respiratory Medicine, NTT Medical Center Tokyo, Tokyo, Japan.
Anticancer research
|December 31, 2024
概括
晚期非小细胞肺癌 (NSCLC) 患者患有肺纤维化,尽管有新的治疗方法,但生存率没有改善. 对于这个患者群体来说,新的策略至关重要,以提高他们的预后.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 医疗治疗的有效性 医学治疗的有效性
背景情况:
- 先进的非小细胞肺癌 (NSCLC) 治疗方法在20年内改善了整体存活率 (OS).
- 与肺纤维化同时存在的NSCLC患者的治疗策略仍未确定.
研究的目的:
- 评估潜在肺部疾病对IV期NSCLC患者的OS的影响.
- 评估NSCLC中不同肺部疾病的OS趋势和治疗疗效.
主要方法:
- 对接受抗瘤药物治疗的581名IV期NSCLC患者的回顾性审查.
- 根据肺部状况 (正常,肺气,纤维化) 和治疗时代 (2002-2021) 的分类.
- 与细胞毒性药物 (CYs),氨酸激酶抑制剂 (TKIs) 和免疫检查点抑制剂 (ICIs) 的OS比较.
主要成果:
- 在过去二十年中,所有NSCLC患者和正常肺部或肺气患者的生存状况显著改善.
- 肺纤维化患者没有显著改善OS (p=0.605).
- 在正常肺和肺气组中,TKI和ICI改善了OS,但在纤维化组中没有改善 (p=0.502).
结论:
- 晚期NSCLC的预后有所改善,但不包括肺纤维化患者.
- 迫切需要新的治疗策略和治疗剂,以改善肺纤维化NSCLC患者的治疗结果.
相关概念视频
01:21Cancer Survival Analysis
290
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
290
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K